Aeterna Zentaris Inc. (AEZS) and uniQure N.V. (NASDAQ:QURE) Comparison side by side

Both Aeterna Zentaris Inc. (NASDAQ:AEZS) and uniQure N.V. (NASDAQ:QURE) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aeterna Zentaris Inc. 2 0.00 15.52M -0.92 0.00
uniQure N.V. 49 0.00 31.15M -2.48 0.00

Table 1 demonstrates Aeterna Zentaris Inc. and uniQure N.V.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows us the return on assets, net margins and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
Aeterna Zentaris Inc. 885,288,916.78% -396.9% -56.4%
uniQure N.V. 63,403,215.96% -48.9% -32.6%

Risk & Volatility

Aeterna Zentaris Inc.’s 1.22 beta indicates that its volatility is 22.00% more volatile than that of S&P 500. Competitively, uniQure N.V. is 8.00% less volatile than S&P 500, because of the 0.92 beta.


The Current Ratio and Quick Ratio of Aeterna Zentaris Inc. are 2.4 and 2.3 respectively. Its competitor uniQure N.V.’s Current Ratio is 9.5 and its Quick Ratio is 9.5. uniQure N.V. can pay off short and long-term obligations better than Aeterna Zentaris Inc.

Analyst Ratings

Aeterna Zentaris Inc. and uniQure N.V. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aeterna Zentaris Inc. 0 0 0 0.00
uniQure N.V. 0 0 4 3.00

On the other hand, uniQure N.V.’s potential upside is 81.33% and its average price target is $74.

Insider & Institutional Ownership

Institutional investors owned 21.4% of Aeterna Zentaris Inc. shares and 78.8% of uniQure N.V. shares. 0.6% are Aeterna Zentaris Inc.’s share owned by insiders. Competitively, 1.8% are uniQure N.V.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aeterna Zentaris Inc. 3.31% -15.82% -30.94% -36.55% 38.89% -14.97%
uniQure N.V. -13.32% -23.63% 2.71% 77.57% 97.14% 103.5%

For the past year Aeterna Zentaris Inc. has -14.97% weaker performance while uniQure N.V. has 103.5% stronger performance.


uniQure N.V. beats on 7 of the 10 factors Aeterna Zentaris Inc.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companyÂ’s product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.